In many embryonic tissues, type IIA procollagen is synthesized and deposited into the extracellular matrix containing the NH 2 -propeptide, the cysteine-rich domain of which binds to bone morphogenic proteins. To investigate whether matrix metalloproteinases (MMPs) synthesized during development and disease can cleave the NH 2 terminus of type II procollagens, we tested eight types of enzymes. Recombinant trimeric type IIA collagen NH 2 -propeptide encoded by exons 1-8 fused to the lectin domain of rat surfactant protein D was used as a substrate. The latter allowed trimerization of the propeptide domain and permitted isolation by saccharide affinity chromatography. Although MMPs 1, 2, and 8 did not show cleavage, MMPs 3, 7, 9, 13, and 14 cleaved the recombinant protein both at the telopeptide region and at the procollagen N-proteinase cleavage site. MMPs 7 and 13 demonstrated other cleavage sites in the type II collagen-specific region of the N-propeptide; MMP-7 had another cleavage site close to the COOH terminus of the cysteine-rich domain. To prove that an MMP can cleave the native type IIA procollagen in situ, we demonstrated that MMP-7 removes the NH 2 -propeptide from collagen fibrils in the extracellular matrix of fetal cartilage and identified the cleavage products. Because the N-proteinase and telopeptidase cleavage sites are present in both type IIA and type IIB procollagens and the telopeptide cleavage site is retained in the mature collagen fibril, this processing could be important to type IIB procollagen and to mature collagen fibrils as well.
Fibrillar collagen types I, II, III, and V are synthesized with globular propeptides at both the COOH and NH 2 termini that are generally removed prior to formation of fibrils. In contrast, there are certain instances in which the collagen fibril retains the NH 2 -propeptide, primarily types I and III in embryonic skin (1) and type IIA during skeletal development. We have shown that the type IIA form of type II procollagen retains the NH 2 -propeptide when synthesized during chondrogenesis and in other embryonic tissues where type II collagen is made, such as notochord, aorta, kidney, and skin (2) (3) (4) . Type IIA pN procollagen is also found in fetal and adult vitreous humor (5, 6) . Processed type I NH 2 -propeptide has been isolated from bovine bone (7) and the type II NH 2 -propeptide from embryonic chicken cartilage (8) . In addition, the NH 2 -propeptides of type I, IIA, and III have been found in serum (9 -11) and used as markers for metabolic activity of the collagen-synthesizing tissues. In type I, and presumably type II and type III procollagens, the NH 2 -propeptide is removed from the procollagen by a specific N-proteinase characterized by Prockop and colleagues (12) . Eyre and colleagues (13) demonstrated that MMP-3 1 (stromelysin) can cleave type II collagen at two locations in the amino telopeptide just a few amino acids COOH-terminal of the N-proteinase cleavage site, thereby acting as a telopeptidase, suggesting the possibility that MMP-3 also can release the propeptide region. The ability of other MMPs to cleave this region is not known.
We have shown recently that the cysteine-rich domain of type IIA procollagen NH 2 -propeptide binds to members of the TGF-␤ superfamily, TGF-␤1 and BMP-2, thereby predicting an important function for the NH 2 -propeptide in the extracellular matrix (3) . Cleavage of the NH 2 -propeptide in the extracellular matrix could have significant effects on the binding or presentation of the BMPs. Support for this hypothesis comes from BMP-binding proteins that are involved in dorsal-ventral patterning: chordin in Xenopus and sog in Drosophila. Chordin and sog are homologues containing the same cysteine-rich domain as the collagen NH 2 -propeptide and bind to BMP-4 and decapentaplegic, respectively (14, 15) . Binding of these BMPs to chordin or sog inhibits interaction of the BMP with its cellular receptors. Furthermore, enzymic cleavage of chordin by the Xenopus enzyme xolloid and sog by the Drosophila enzyme tolloid serves to activate the bound BMP (14, 15) .
The type IIA pN-procollagen containing the cysteine-rich domain is deposited in the extracellular matrix providing potential localization of BMP in the insoluble compartment of the extracellular matrix. In analogy to cleavage of chordin and sog, the NH 2 -propeptide could be liberated by cleavage from the pN-procollagen. Cleavage of the procollagen in different domains would theoretically produce two different types of fragments. If cleavage takes place at the telopeptide the trimeric NH 2 -propeptide would be released; if cleavage takes place near the BMP-binding domain, monomeric cysteine rich domains could be liberated. Likely candidates for extracellular cleavage of pN procollagen are the MMPs and astacin proteinases such as tolloid and BMP-1 (procollagen C-proteinase). The purpose of this study was to determine the cleavage specificity of the potentially relevant MMPs. We tested MMPs 1, 2, 3, 7, 8, 9, 13, and 14 and found that MMPs 3, 7, 8, 9, 13 , and 14 were capable of specific cleavage of the type IIA procollagen NH 2 -propeptide at various sites. All enzymes cleave in domains common to both type IIA and type IIB procollagen, whereas MMPs 7 and 13 also cleave in the type II-specific minor helix and MMP-7 cleaves in the type IIA-specific cysteine-rich domain.
In preliminary studies, we observed that recombinant propeptides of type IIA procollagen expressed in prokaryotic or eukaryotic cells are secreted as monomers. To study the cleavage of a trimeric propeptide domain, we utilized a previously characterized chimera consisting of the propeptide domain of IIA procollagen linked to a surfactant protein D (SPD) sequence that encodes a contiguous coiled-coil trimerization domain and a C-type lectin domain (16) . The recombinant protein is secreted as a trimeric protein with a triple-helical minor helix and can be readily isolated by saccharide affinity chromatography on maltosyl-agarose.
EXPERIMENTAL PROCEDURES
Preparation of the Substrates-Triple-helical type II procollagen Npropeptide was prepared as a fusion protein with the neck region and lectin domain of rat SPD 2 (16) . Briefly, a IIA-SPD chimeric construct was synthesized by linking the cDNA encoding exons 1-8 of the human type II procollagen gene to the cDNA encoding the neck region and the carbohydrate recognition domain of rat SPD (Fig. 1, C and D) . PCR overlap extension was used to create IIA-SPD cDNA in pGEM-3Z (17, 18) . The generated construct was excised from pGEM-3Z and ligated into the multiple cloning site of pEE14 (18) . With this vector, stably transfected clones of Chinese hamster ovary-K1 cell were established using methionine sulfoximine as a selectable marker. To obtain IIA-SPD, the clones were cultured in glutamine-free Glasgow's minimum essential medium (Sigma) containing 10% dialyzed fetal calf serum (HyClone, Logan, UT) and 50 g/ml ascorbic acid (Sigma) with 100 -1000 M methionine sulfoximine (Sigma). The purification of IIA-SPD followed the method previously used for recombinant rat SPD (18) . Briefly, medium from cultured cells was dialyzed against Tris-buffered saline, pH 7.5, containing 10 mM EDTA and 0.2 mM phenylmethanesulfonyl fluoride. Following recalcification, IIA-SPD was isolated by affinity chromatography on maltosyl-agarose (Bio-Rad).
MMP Cleavage-Recombinant human MMPs 1 (collagenase-1), 3 (stromelysin-1), 7 (matrilysin), 8 (neutrophil collagenase, collagenase-2), and 14 (catalytic domain, MT1-MMP) were purchased from Chemicon International (Temecula, CA). Recombinant human MMPs 2 (gelatinase A) and 9 (gelatinase B) were provided by Dr. Robert Senior (Washington University, St. Louis, MO). Purified rat MMP-13 (collagenase-3) was obtained from Dr. John Jeffrey (Albany Medical College, Albany, NY). Except for MMP-7 lacking propeptide domain and the catalytic domain of MMP-14, all the MMPs were activated by the incubation with 1 mM 4-aminophenylmercuric acetate for 1-24 h at 37°C.
For cleavage experiments, IIA-SPD and recombinant rat SPD were dialyzed against MMP cleavage buffer (0.2 M NaCl, 10 mM CaCl 2 , 50 mM Tris, pH 7.5) and adjusted to a final concentration of 100 ng/l. Cleavage was performed by incubating the substrates with each MMP at 37°C for 24 h or as indicated, at an enzyme to substrate ratio of 1:50 w/w (for MMPs 1, 2, 3, 8, and 14) or 1:100 (for MMPs 7, 9, and 13). The ratios were determined by the efficiency of cleavage for the respective enzymes. The cleavage was then terminated by the addition of EDTA to a final concentration of 20 mM.
Analysis of the Cleaved Products-The cleaved products of IIA-SPD were analyzed by silver staining and Western blotting. After the incubation with MMPs, the substrates were loaded onto 4 -20% SDS-polyacrylamide gel (Gradipore, North Ride, New South Wales, Australia) and electrophoresed under reducing conditions with 0.1 M dithiothreitol, together with standard proteins (Benchmark™ prestained protein ladder, Invitrogen). The proteins were then visualized on the gel by silver staining. Western blot analysis was performed to determine which parts of the recombinant protein were contained in each fragment. For this, the samples were loaded under both reducing and nonreducing conditions, depending on the antibodies used. Proteins on the gel were then transferred to a supported nitrocellulose membrane (Hybond-C Extra, Amersham Biosciences, Inc.) overnight at 30 V in Tris/glycine transfer buffer, pH 8.3, containing 20% methanol. The membrane was blocked with 5% nonfat dry milk (Bio-Rad) in phosphate-buffered saline (PBS) and then incubated overnight at 4°C in 1% dry milk in PBS, containing the primary antibody.
Rabbit antisera against recombinant human IIA-glutathione S-transferase (2) was used as a primary antibody to detect the exon 2-encoded region in the propeptide domain of IIA-SPD (Fig. 1D ) (IIA antiserum). Chicken IgY reactive with the region encoded by exons 3-8 of human type II procollagen, which includes NH 2 -propeptide and telopeptide domains of type IIB procollagen (Fig. 1D) , was obtained from the yolks of the eggs from the chickens immunized with a glutathione S-transferase fusion protein (3) containing this area (anti-IIE3-8). The specificity of this antibody against rat SPD or exon 2-encoded region of type IIA procollagen was confirmed (data not shown). The neck region and carbohydrate recognition domain in IIA-SPD was detected by SPD antiserum (19) (Fig. 1D) . For the detection of exon 2-encoded region, the samples were analyzed under nonreducing conditions because IIA antiserum does not strongly react with the reduced epitopes. For the other two antibodies, the samples were analyzed under reducing conditions with 0.1 M dithiothreitol as for gel staining. The primary antibodies were used at the concentrations of 1:1000 (IIA and SPD antisera) or 1:500 (anti-IIE3-8) in 1% dry milk in PBS. After washing in PBS, the membranes were incubated with appropriate secondary antibodies coupled to horseradish peroxidase at the concentration of 1:2000 in 1% dry milk in PBS at room temperature for 1 h. The analyses were accomplished by chemiluminescence on autoradiography films (ISO-MAX, Scimart, St. Louis, MO), using enhanced chemiluminescent reagents for horseradish peroxidase (SuperSignal™ West Pico, Pierce).
NH 2 -terminal amino acid sequencing was performed to determine the exact cleavage sites. Cleaved fragments were separated by SDSpolyacrylamide gel electrophoresis and transferred to polyvinylidene membrane (Sequi-Blot PVDF membrane, Bio-Rad). Protein bands were visualized by staining with Coomassie Brilliant Blue R-250, excised, then sequenced with an ABI 473A protein sequencer equipped with the model 610A data analysis software. For the bands with multiple sequences, initial and repetitive yields were used to assign identity of the cleavage site.
Cleavage of Native Type IIA Procollagen by MMP-7 in Tissue Sections-Tissues from a 9-week gestation human fetus (provided by the Central Laboratory for Human Embryology, University of Washington, Seattle, WA) were frozen in OCT compound (Miles Laboratories, Elkhart, IN), and 10-m-thick sections were prepared with a cryostat and placed on a polylysine coated glass slides (Fischer Scientific, Pittsburgh, PA). After initial preliminary experiments to establish enzyme to substrate levels, time of digestion, and washing conditions, 12 serial sections were subjected to MMP-7 digestion. They were divided into three sets of four serial sections. In each set, three sections were incubated with 50 l of MMP cleavage buffer containing 5, 10, or 20 ng/l MMP-7. The other one was treated with the same buffer containing both 10 ng/l MMP-7 and 20 mM EDTA and served as a control (EDTA control). After the incubation at 37°C for 24 h, the sections were washed in PBS containing 0.05% Triton X-100 at room temperature for 60 min to remove the cleaved fragments.
Immunofluorescence Staining-After MMP-7 treatment, the sections were washed in PBS and fixed in 4% paraformaldehyde PBS solution for 10 min at room temperature. They were then treated with 1 mg/ml hyaluronidase (type III, Sigma) in PBS for 30 min at 37°C, and blocked with 10% (v/v) normal donkey serum in PBS for 1 h at room temperature. Double immunostaining was performed. To detect type IIA NH 2 -propeptide, antiserum was used at a dilution of 1:400. To detect the major triple-helical domain, rat antiserum against bovine type II collagen (a gift from Dr. Michael Cremer, University of Tennessee, Memphis, TN) was used at the concentration of 1:40. The sections were incubated at 4°C overnight in PBS containing the designated sera with 1% (v/v) normal donkey serum. Two other sections were incubated with normal rabbit and rat sera at the same concentrations and served for the normal sera control. After washing in PBS, the sections were incubated sequentially with secondary antibodies for the respective primary antibodies: cyanine 3-conjugated donkey anti-rabbit IgG F(abЈ) 2 fragment with a dilution of 1:200 and FITC-conjugated donkey anti-rat IgG F(abЈ) 2 fragment with a dilution of 1:100. Finally, the sections were washed in PBS and mounted in fluorescent mounting medium (DAKO, Carpinteria, CA). All the normal sera and the secondary antibodies were purchased from Jackson Immunoresearch Laboratories (West Grove, PA).
Because MMP-7 does not cleave fibrillar type II collagen (data not shown), cleavage by MMP-7 in the exon 2-8-encoded region of native type IIA procollagen was evaluated quantitatively by the fluorescence intensity. Immunoreactivity for the exon 2-encoded region in NH 2 -propeptide was compared with that for the major triple-helical domain of type II collagen (Fig. 1A) . Fluorescence intensity was measured by confocal laser-scanning microscopy. The images for quantification were collected with a Bio-Rad MicroRadiance confocal microscope system mounted on a Nikon E800 upright fluorescence microscope, using BioRad LaserSharp 2000 software (version 3.1). Confocal FITC images were collected at the excitation of 488 nm by the argon gas laser, obtaining fluorescence with a 515 Ϯ 30 nm band pass filter. For cyanine 3, excitation was at 514 nm and a 600 nm long pass filter was used. For these, a Nikon 60ϫ (1.4 numeric aperture) oil immersion objective was used.
Because type IIA procollagen was found at high levels at the periphery of the developing cartilage, the change of the fluorescence following MMP-7 treatment was evaluated in this area. On each section, three fields of 205 ϫ 205 m were randomly chosen, and five images were obtained in each field with the optical sectioning of 2 m thickness and stored in a format of 256 ϫ 256 full frame with a pixel depth of 8 bits. The images were obtained in the same manner for the MMP-7-treated sections, EDTA control sections, and normal sera control sections. To obtain an overview of the staining, lower magnification images of the sections were obtained with a Nikon 20ϫ (0.75 numeric aperture) dry objective and stored in a format of 1024 ϫ 1024 full frame with a pixel depth of 8 bits. The overlaid images were generated using LaserSharp software.
In each field, three images from the middle three layers obtained by optical sectioning were used for quantitative evaluation. Using LaserSharp software, the intensity values of all the pixels were averaged on each image for both cyanine 3 and FITC, and their ratio was obtained. The ratios were then compared among the MMP-7-treated sections and the EDTA controls by one-way factorial analysis of variance on a Statview software package (version 5.0, SAS Institute, Cary, NC). When necessary, Bonferroni and Dunn's procedure was employed as a post hoc test. The level of significance was set at p Ͻ 0.05.
Cleavage of Type IIA Procollagen in Fetal Tissues-Bone and cartilaginous tissues were obtained from a 6-week gestation human fetus. Two hundred milligrams wet weight of tissues were homogenized at 4°C in 2 ml MMP cleavage buffer containing 1 mM phenylmethylsulfonyl fluoride (Sigma) and 10 mM N-ethylmaleimide, using an overhead stirrer (Wheaton Science, Millville, NJ). For cleavage, 2 g of MMP-7 was added to the homogenate and incubated at 37°C under continuous agitation. Four hundred microliters of the homogenate were obtained at 0, 2, and 12 h, and 800 l was recovered at 24 h. In each aliquot, the cleavage was terminated by addition of EDTA at a final concentration of 20 mM, then the samples were stored at Ϫ80°C. Analysis of cleavage products was performed by Western blot with anti-IIE3-8. The 24-h sample was further analyzed with IIA antiserum to identify the bands containing exon 2-encoded region. For these, 400 l of the homogenate was centrifuged at 21,000 ϫ g for 5 min at 4°C, and the supernatant was obtained. After desalting and concentration the supernatant was loaded on a gel. Western blotting was done as described. Either reducing or nonreducing conditions were used for the analysis, depending on the antibodies.
RESULTS

MMP Cleavage of Recombinant Rat SPD and IIA-SPD-
Under reducing conditions, recombinant rat SPD and IIA-SPD (Fig. 1, C and D) appeared as bands of 43 and 47 kDa, respectively (Fig. 2) . None of the MMPs tested showed detectable cleavage of recombinant rat SPD under the conditions used in this study ( Fig. 2A) . IIA-SPD was efficiently cleaved by MMPs 3, 7, 9, 13, and 14, whereas MMPs 1, 2, and 8 did not show significant cleavage (Fig. 2B) . Because rat SPD was resistant to MMP cleavage, we inferred that cleavage of IIA-SPD occurred within the procollagen domain. Accordingly, our subsequent experiments focused on the cleavage of IIA-SPD by MMPs 3, 7, 9, 13, and 14. The cleavage patterns for these MMPs were similar (Fig. 2B) . Two bands of ϳ17 and 20 kDa were common to all, and these MMPs also generated an additional band of ϳ25 kDa. MMPs 7 and 13 generated components of higher apparent molecular mass, between 34 and 30 kDa.
Next, the time course of the cleavage was studied for all the MMPs. The results for MMPs 9 and 14 are shown in Fig. 3 . MMP-9 digested IIA-SPD completely at 24 h (Fig. 3A) , whereas MMP-14 did not cleave the protein completely even at 48 h (Fig. 3B ). In the cleavage by MMP-9, a faint band at 32 kDa was seen only for the first 1 h of incubation, but all the other bands appeared at 0.5 h and remained unchanged up to 48 h.
The pattern of cleavage by MMP-14 was consistent throughout the incubation period. For both of these enzymes, the fragment at 20 kDa was likely derived from a preferred cleavage sites, as this band was more prominent than the others. Similarly, MMPs 3, 7, and 13 showed a consistent pattern of cleavage from 0.5 to 48 h (data not shown). From the result of control incubations in which the activity of MMPs was inhibited by addition of 20 mM EDTA, it was confirmed that all of the products are generated by MMP cleavage, not from the action of contaminating proteinases.
Western Blot Analysis and Amino Acid Sequencing of the Cleaved Fragments-All the major bands visualized by gel staining were recognized by at least one of the three antibodies used in this study, confirming they were cleavage products of IIA-SPD. For each MMP, these bands were numbered sequentially according to their molecular sizes.
Four major bands were identified following cleavage with MMP-3 (Fig. 4A) . In Western blot analysis, bands 1 and 2 were recognized by both IIA antiserum and anti-IIE3-8, whereas bands 3 and 4 were detected only by SPD antiserum. From the results, MMP-3 was inferred to cleave IIA-SPD at two sites between the epitopes for anti-IIE3-8 and those for SPD anti- serum (Fig. 1D) , generating two pairs of fragments. Subsequently, bands 3 and 4 were subjected to amino acid sequencing as they contained the epitopes for the SPD antiserum. The results of microsequencing showed that each of the bands contained two fragments cleaved at consecutive sites ( with the previously reported result on cleavage of the mature form of native bovine type II collagen (13) . Digestion by MMP-7 produced six bands as seen by gel staining (Fig. 4B) , and bands 3-6 showed the same pattern of immunostaining as that with MMP-3, i.e. bands 3 and 4 were detected by both IIA antiserum and anti-IIE3-8, and bands 5 and 6 were recognized only by SPD antiserum. Therefore, MMP-7 appears to have two cleavage sites at or near the sites of cleavage for MMP-3. In contrast, the top two bands were unique for MMP-7. Band 1 was recognized by anti-IIE3-8 and SPD antiserum but not by IIA antiserum, and the cleavage for this band should occur between the epitopes for IIA antiserum and those for anti-IIE3-8 (Fig. 1D) . Band 2 was recognized only by SPD antiserum, and the cleavage between anti-IIE3-8 recognition sites and the SPD antiserum recognition sites could generate this band, upstream of the MMP-3 cleavage sites. Subsequently, bands 1, 2, 5, and 6 were subjected to amino acid sequencing ( Table I (Fig. 4C) . Among them, band 1 was detected by both IIA antiserum and anti-IIE3-8, and bands 2 and 3 were visualized only by SPD antiserum (Fig. 4C) . The pattern was similar to that with MMP-3, and the cleavage sites with MMP-9 were considered to be same or close to those with MMP-3. The lower two bands recognized by SPD antiserum were subjected to amino acid sequencing (Table I MMP-13 cleavage produced five bands, and the result of immunostaining was the same as that obtained for bands 2-6 generated by MMP-7 cleavage (Fig. 4D) (Table I) . Among the five bands, bands 1, 4, and 5 were analyzed by amino acid sequencing (Table I) (Fig. 4E) . Western blotting showed the cleavage pattern was same as that produced by MMP-3; bands 1 and 2 were recognized by anti-IIE3-8 and SPD antiserum, and bands 3 and 4 were detected only by SPD antiserum. Microsequencing was performed on bands 3 and 4. Band 3 contained one fragment cleaved at Ala 156 -Gln 157 , and another cleavage site in N-telopeptide region at Gly 172 -Val 173 was determined in band 4 (Table I) .
Cleavage sites recognized by all MMPs tested are shown in the amino acid sequence of type IIA procollagen (Fig. 5) . As noted, all the MMP cleavage sites are distributed in the nonGly-X-Y portions of type IIA procollagen domain in IIA-SPD, and the exon 2-encoded region contains only one cleavage site by MMP-7. MMPs 3, 9, and 14 cleave this NH 2 -propeptide domain at Ala 156 -Gln 157 , which is also the procollagen N-proteinase cleavage site. MMPs 7 and 13 did not cleave this site but cleaved one residue downstream. All the enzymes have at least one cleavage site in N-telopeptide region downstream of Lys 165 , which is a known cross-link site for the type II collagen fibril (21, 22) .
Cleavage of NH 2 -propeptide in Tissue by MMP-To determine whether the NH 2 -propeptide can be cleaved by MMPs in native tissue, frozen tissue sections and fresh tissues from human fetuses were subjected to MMP-7 treatment. MMP-7 was chosen because it can cleave type IIA procollagen efficiently in NH 2 -propeptide and N-telopeptide regions, whereas it does not cleave fibrillar domain of type II collagen. Fetal tissue was chosen because type IIA procollagen is expressed at a high level during chondrogenesis (3) .
In the experiment with tissue sections, sections treated with normal sera instead of the primary antibodies showed virtually no fluorescence for both cyanine 3 and FITC (Table II) , and the specificity of immunofluorescence staining was confirmed. Because type IIA procollagen is found at high levels at the perichondrium and periphery of the developing cartilage, the change in the fluorescence by MMP-7 treatment was evaluated in this area. On the EDTA control sections, strong fluorescence of cyanine 3 bound to IIA antiserum was observed at the periphery of the cartilage, where type IIA procollagen reacts with both antibodies. Fluorescence of FITC bound to the antibody against major triple-helical domain of type II collagen was more evident in the central area where primarily type IIB procollagen is found (Fig. 6, A and B) . The intensities of red and green fluorescence were measured in arbitrary sets and the change in fluorescence was evaluated by their ratio as described under "Experimental Procedures." The tissues were treated with the three graded concentrations of MMP-7. Dosedependent removal of the NH 2 -propeptide domain was observed in the peripheral region as indicated by a decrease in the ratio of red to green fluorescence (Fig. 6, C and D; Table II) . FIG. 4 . Detection of MMP cleavage products of IIA-SPD by Western blotting. IIA-SPD was incubated with each of MMPs 3, 7, 9, 13, or 14 at 37°C for 24 h as for gel staining and was separated by SDS-polyacrylamide gel electrophoresis under reduced conditions with dithiothreitol (for anti-IIE3-8 and SPD antiserum) or unreduced conditions (for IIA antiserum). The samples were then transferred to supported nitrocellulose membranes, and the bands were detected by three kinds of antibodies that recognize specific sites of IIA-SPD (Fig. 1D) . Results with MMPs 3, 7, 9, 13, and 14 are shown in panels A, B, C, D, and E, respectively. In these panels, all the major bands visualized by gel staining were numbered sequentially according to their molecular sizes for their reference, and the correspondence of the bands are shown by gray lines. The result of immunostaining was displayed in a box placed right in each panel, with the schematic of the antibody recognition sites.
Upon treatment with the MMP-7, the reactivity to the NH 2 -propeptide antibody decreased, whereas reactivity to the fibrillar domain remained the same, strongly suggesting removal of the NH 2 -propeptide.
Cleavage products by MMP-7 were analyzed by Western blotting using anti-IIE3-8 (Fig. 7A) . Before cleavage, a single band was observed at 20 kDa. As the cleavage progressed, other bands of higher molecular mass were released from the tissue, and five bands were recognized in 24-h sample. Two of them, bands 2 and 4, were also recognized by IIA antiserum, indicating that they contain exon 2-encoded region (Fig. 7B) . and Leu 68 by MMP-7, all the cleavage sites were in the interrupted portion and N-telopeptide region, and no cleavage sites existed in Gly-X-Y sequence regions. All the MMPs had cleavage sites at the same site or one residue to the COOH-terminal side of the procollagen N-proteinase cleavage site, and all of them had at least one cleavage site between Ala 169 and Gln 175 in N-telopeptide region. In this figure, the amino acid sequence encoded by exon 2 is shown in pink letters and the sequence specific to type II procollagen in blue. Gly-X-Y sequence has gray background, and the numbers below the sequence indicate the encoding exons. #, deoxypyridinoline cross-link formation site in Ntelopeptide region (Lys 165 ); *, previously reported cleavage sites (13). The amino acid numbers are shown at the ends of lines. 
TABLE I The amino acid sequences determined in the MMP cleaved fragments of IIA-SPD
The glutamine residue at the NH 2 -terminal of the secreted form of type IIA procollagen was numbered as the first amino acid. The ratio of two sequences detected from one band is shown in parentheses. Sequences from the chimeric part of rat SP-D are underlined. *, sequence from the previously reported cleavage site (13 For interpretation of the banding pattern, it is important to note that the native protein contains a hydroxylysine-derived cross-link in the N-telopeptide, whereas the recombinant protein does not. Comparing these results with the distribution of the cleavage sites of recombinant NH 2 -propeptide by MMP-7, the five bands were considered to be single or multiple NH 2 -propeptides of type IIA and IIB procollagen removed from the major triple-helical domain (Fig. 7C) , i.e. bands 1 and 2 were likely single NH 2 -propeptides of type IIB and type IIA procollagen, respectively, cleaved at the procollagen N-propeptidase cleavage site. Bands 3, 4, and 5 are likely multiple propeptides bound each other by the deoxypyridinoline cross-link in Ntelopeptide region. From the reactivity for IIA antiserum, band 4 was considered to originate from type IIA procollagen, and bands 3 and 5 were from type IIB procollagen.
DISCUSSION
The NH 2 -propeptide of type IIA procollagen is present in the extracellular matrix of developing tissues including cartilage (2, 3) . Electron microscopy has identified IIA procollagen fibrils in both developing cartilage and in adult vitreous humor (3, 6) . There is increasing evidence that the NH 2 -propeptide of type IIA procollagen may have growth factor-regulating activity. Recombinant IIA propeptides have been shown to bind TGF-␤1 and BMP-2 in vitro (3), whereas, in vivo, full-length type IIA procollagen was shown to function similarly to chordin during Xenopus development by inactivating BMP (23) . Another level of BMP regulation exists where the astacin protease tolloid (in Drosophila) or Xolloid (in Xenopus) can cleave the chordin-BMP complex, thus releasing active BMP (15, 24) . The present study extends this paradigm for the IIA NH 2 -propeptide as we have shown the presence of numerous MMP cleavage sites, and cleavage at specific sites in the propeptide could potentially release the active growth factor for binding to its receptor. As these cleavage sites were defined using recombinant protein as the substrate, we further demonstrated the ability of one MMP, MMP-7, to cleave type IIA procollagen in situ. Previously, Bishop et al. (5) showed that the NH 2 -propeptide could be removed from the native pN-procollagen by type I procollagen N-proteinase. Thus, cleavage of the BMP-binding cysteine-rich domain of type IIA procollagen may be an important process of growth factor regulation in skeletal development as well as in the development of other tissues. Fig. 8 shows a schematic representation of the results of cleavage with all MMPs tested in this study. In addition to the importance of type IIA collagen NH 2 -propeptide cleavage, all of these MMPs can cleave type IIB NH 2 -propeptide and mature type II collagen as well. When cleavage occurs in the N-telopeptide region (site D), the NH 2 -propeptide is removed as an intact triple-helical trimer. Indeed, we have shown by biophysical methods that MMP-9 liberates trimeric triple-helical NH 2 -propeptide. 2 The cleavage at this site suggests that, even when these MMPs work on the mature collagen, the lysine cross-link would be released and the collagen fibril would be more susceptible to disruption, in analogy to the cleavage of the telopeptide by MMP-3 discovered by Wu and Eyre (25) . In fact, degradation by MMP-3 was shown to change the composition and physical properties of the cartilage (26) , and a similar phenomenon could be expected from digestion with the other MMPs described here. Cleavage at the N-proteinase cleavage site (site C) would produce a similar trimeric peptide without disturbing the minor triple helix or cross-link site. Therefore, cleavage at sites C or D would produce a triple-helical trimeric NH 2 -propeptide that could retain the ability to bind to BMPs. By contrast, cleavage at site A would release monomeric cysteinerich domains that, in analogy to chordin, would liberate BMPs to bind to their receptors (14) . Similarly, cleavage at site B is predicted to release the NH 2 -propeptide in a monomeric form that could have reduced growth factor binding efficiency. These functional studies are in process.
Our studies strongly suggest that the NH 2 -propeptide can be removed from the fibrillar collagen domain by enzymes other than the type I collagen N-proteinase. The possibility of proteinase redundancy has been suggested from at least two previous studies. First, cartilage structure was not affected by a genetic inactivating mutation of N-proteinase (dermatosparaxis or Ehlers-Danlos syndrome type VIIC (27) . Second, fibril- logenesis in cartilage was apparently unaffected following knock-out of ADAMTS-2 (type I collagen N-proteinase) (28) . In addition, other proteinases have been shown to cleave the propeptide or telopeptide. For example, Wu and colleagues (21) showed that MMP-3 (stromelysin) could cleave intact type II collagen fibrils from mature extracellular matrix. The localization of type II procollagen processing has not been determined; however, it is thought to occur during the process of secretion from the cell as described for type I procollagen (29) . Interestingly, MMP-14, shown here to act as both an N-proteinase and a telopeptidase, is a membrane-bound enzyme that could be well positioned for processing procollagen.
In tissues where type II collagen is a major constituent of the extracellular matrix, it is likely that processing of this molecule by MMPs is an important mechanism during development. In particular, the IIA splice variant of type II procollagen is the form expressed in developing cartilage by pre-chondrocytes (30, 31) ; thus, processing of the IIA NH 2 -propeptide may be important in regulating growth factor activity. Among the MMPs shown to cleave the IIA NH 2 -propeptide in this study, MMPs 3, 9, and 14 were shown to be expressed during the early stages of cartilage development (32) (33) (34) . Cleavage within the N-telopeptide of type IIA procollagen by MMPs could also occur in the hypertrophic site of the developing skeleton. Recent evidence suggests that cleavage of type IIA procollagen NH 2 -propeptide could play a role in remodeling of the growth plate. Type IIA procollagen has been localized in the hypertrophic region of the growth plate (3, 35) , and MMPs 9 and 13 appear to play major roles in the cartilage to bone transition at the growth plate (33, 36, 37) . MMP-14 has been shown to be expressed in the hypertrophic chondrocyte (34) , by which cartilage is gradually replaced by bone and IIA NH 2 -propeptide is removed (3). Therefore, the cleavage by MMPs of the NH 2 -propeptide potentially bearing BMPs could be important in angiogenesis or osteogenesis at the cartilage-bone interphase. The expression of MMPs is, of course, not enough to say the enzymes are actually active in the developing skeleton. MMPs are synthesized as inactive pro-forms that require subsequent activation in the matrix. In addition, another level of MMP regulation exists in the form of tissue inhibitors of metalloproteinases. Because the in situ activity of MMPs during skeletal development is not well defined, further studies are necessary to verify that the NH 2 -propeptide is indeed cleaved by MMPs in the developing embryo. Demonstration of active MMP cleavage with tissue extracts or detection of the predicted cleavage sites on tissue sections would provide sound evidence to compliment the findings of the present study.
In osteoarthritic cartilage, but not in normal adult articular cartilage, type IIA procollagen is synthesized and deposited around the cells (35, 38) . MMPs 3, 9, 13, and 14 are also known to be elevated with most of the matrix degrading activity attributed to MMP-13 (39) . MMP-7 also plays a role in OA (40) and could contribute to the liberation of the NH 2 -propeptide. In studies designed to test whether free NH 2 -propeptide is present in the serum, the type IIA-specific antibody was used in an enzyme-linked immunosorbent assay to detect NH 2 -propeptide (10).
The NH 2 -propeptides of fibrillar procollagens types I, II, and III are thought to be processed similarly; however, type II procollagen may possess intrinsic qualities that make the processing of the NH 2 -propeptide different from processing of type I procollagen. First, type II procollagen is a homotrimer of three identical ␣ chains, whereas type I procollagen contains the cysteine-rich domain only in the ␣1(I) chain, not in the ␣2(I) chain; therefore, the trimeric NH 2 -propeptide may be different in structure. Second, type II procollagen contains a triplehelical domain (minor helix) in the NH 2 -propeptide that is almost twice as long as the type I minor helix (Figs. 1B and 5) , allowing for further extension from or through the fibril. Third, the type II propeptide minor helix contains a 5-amino acid interruption that provides cleavage sites for MMPs 7 and 13. Finally, the amino acid sequence of the telopeptide of type I procollagen is different from type II procollagen and does not contain the enzyme cleavage sites for MMPs reported here. For N-proteinase activity, type I procollagen apparently requires a hairpin loop at the telopeptide (41); however, the three-dimensional structure of type II procollagen N-proteinase cleavage site has not been reported.
It seems increasingly clear that functional changes occur within microenvironments of the extracellular matrix that can dramatically affect both matrix and cell function. Cleavage of the type II collagen fibril by MMPs could allow swelling of the tissue and permit new molecules to be incorporated into the matrix. Removal of the NH 2 -propeptide could have profound effects both functionally and structurally. The growth factor could be redistributed either in an inactive or active state, new molecules could be attracted to the collagen, or lateral association of adjacent collagen fibrils could result in significant changes in matrix architecture.
